Jennison Associates
CDTX

Jennison Associates’s Cidara Therapeutics CDTX Stock Holding History

Jennison Associates’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-396,015
Closed -$37.9M – 594
2025
Q3 		$37.9M Buy
396,015
+346,803
+705% +$22.1M 0.02% 263
2025
Q2 		$2.4M Buy
+49,212
New +$1.18M ﹤0.01% 431

Other funds holding CDTX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Jennison Associates's CDTX Position: Q4 2025 in Review

Jennison Associates sold out of Cidara Therapeutics (CDTX) in Q4 2025, closing a stake of 396,015 shares — an estimated $37.9M sold.

Jennison Associates first reported a position in CDTX in Q2 2025 and held it in 2 quarters. The position peaked at $37.9M in Q3 2025. 255 funds tracked by Wall St. Rank hold CDTX as of Q4 2025.

  • Jennison Associates reported no remaining Cidara Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Jennison Associates sold 396,015 Cidara Therapeutics shares in Q4 2025, an estimated $37.9M.
  • Jennison Associates first reported a position in Cidara Therapeutics in Q2 2025 and held it in 2 quarters.
  • Jennison Associates's Cidara Therapeutics position peaked at $37.9M in Q3 2025.
  • 255 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q4 2025.

Based on Jennison Associates's 13F filing for Q4 2025, filed 30 Jan 2026.